ResearchProgress on the Safetyand Efficacy of Remimazolam in Clinical Application/LIU Shuai， ZHANG Weiwei.//Medical Innovationof China，2025，22(17)：161-165

    [Abstract]Remimazolam is a very short-acting intravenous benzodiazepine (BZD) drug developed by the pharmaceutical company PAION AG.In clinical application， compared with other anesthetic and sedative drugs， suchas MidazolamandPropofol，Remimazolamhas theadvantagesofrapidonset，highclearancerate，shortduration ofaction，quickrecovery，stablehemodynamicsandsmallrespiratoryinhibitoryeffct.Thisarticlereviewsthe pharmacological characteristics and clinical application research of Remimazolam，providing a reference for safe clinical medication.

    [Key words] Remimazolam Safety Efficacy

    First-author'sddress：epartmentofnesthesiology，inzhouedicalUversityHospital，hou 256603， China

    doi：10.3969/j.issn.1674-4985.2025.17.037

    在安全性方面，瑞马唑仑(Remimazolam，CNS7056)的血流动力学作用稳定，对呼吸和心血管系统的抑制作用较小]。同时，其药代动力学特性使得长时间或大量输注使用也不易发生蓄积，肝肾功能不全的患者也显示出较好的耐受性。此外，瑞马唑仑的特异性拮抗剂氟马西尼可快速逆转其镇静作用[2，进一步提高了其安全性。在有效性方面，瑞马座仑起效快、代谢快、镇静恢复快，适用于各种需要快速镇静和恢复的场景，如无痛内镜诊疗术、全身麻醉诱导及维持等 ......